Details of Oculis’ presentation:ECTRIMS 2025:Reduction in Retinal Ganglion Cell Loss and Improved Low Contrast Visual Acuity with Privosegtor in Acute Optic Neuritis: Results from a Multicenter Randomized Placebo-Controlled Double-Masked Trial. Privosegtor has received orphan drug designation from both the FDA and the EMA for acute optic neuritis. About Acute Optic NeuritisAcute optic neuritis is a rare condition characterized by acute inflammation of the optic nerve, which can lead to permanent visual impairment. The acute inflammatory process of acute optic neuritis results in the loss of myelin covering the optic nerve and its axons. To date there is no neuroprotective therapy approved for acute optic neuritis and unmet needs remain for medicines that can prevent vision loss after an acute episode of optic neuritis.